phenyl-2-aminoethylselenide has been researched along with Prostatic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljuffali, I; Amin, R; Arnold, RD; Eggert, M; Fu, X; Kang, JY; May, SW; Mouli, S; Nie, B; Oldham, CD; Sheil, A; Waddey, K | 1 |
1 other study(ies) available for phenyl-2-aminoethylselenide and Prostatic Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models.
Topics: Animals; Antineoplastic Agents; Antioxidants; Area Under Curve; Cardiomegaly; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Ethylamines; Gene Expression Regulation; Half-Life; Humans; Injections, Intravenous; Liposomes; Male; Mass Spectrometry; Metabolic Clearance Rate; Mice, Nude; Myocytes, Cardiac; Organoselenium Compounds; Oxidative Stress; Prostatic Neoplasms; Rats, Inbred F344; Reactive Oxygen Species; Technology, Pharmaceutical; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |